Shares of Cassava Sciences Inc. dropped over 10% in after-hours trading following a settlement with U.S. securities regulators over misleading claims about an Alzheimer’s clinical trial. The pharma company and two former executives were charged for the deceptive statements, leading to the stock decline. This development highlights the impact of regulatory actions on stock performance in the pharmaceutical sector.
Full Article
Intel Names Lip-Bu Tan as New C.E.O. Amid Turnaround Efforts
Intel, a struggling semiconductor company, has appointed Lip-Bu Tan as its new CEO to help restore its reputation and market share. Tan, a seasoned business leader, faces the challenge of revitalizing the company after years of decline, including job cuts and loss of market value. Investors have responded positively to Tan's appointment, with Intel's stock price rising over 11% in aftermarket trading. Full Article
Read more